Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial"

Circulation. 2020 Sep 8;142(10):e129-e130. doi: 10.1161/CIRCULATIONAHA.120.049841. Epub 2020 Sep 8.

Authors

Thomas A Zelniker¹, Itamar Raz², Marc S Sabatine³, Stephen D Wiviott³

Affiliations

¹ Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria (T.A.Z.).
² The Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Israel (I.R.).
³ TIMI (Thrombolysis in Myocardial Infarction) Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.S.S., S.D.W.).

PMID: 32897752
DOI: 10.1161/CIRCULATIONAHA.120.049841

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Atrial Fibrillation* / epidemiology
Benzhydryl Compounds / adverse effects
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / drug therapy
Glucosides / adverse effects
Humans

Substances

Benzhydryl Compounds
Glucosides
dapagliflozin